Activation of concurrent apoptosis and necroptosis by SMAC mimetics for the treatment of refractory and relapsed ALL

Scott McComb(University of Ottawa), Beat Bornhäuser(University Children's Hospital Zurich), Martin Schrappe(University Hospital Schleswig-Holstein), Blerim Marovca(University Children's Hospital Zurich), Gunnar Cario, Jean‐Pierre Bourquin(University Children's Hospital Zurich), Júlia Aguadé-Gorgorió(University of California, Los Angeles), Arend von Stackelberg(Charité - Universitätsmedizin Berlin), Cornelia Eckert(Humboldt-Universität zu Berlin), Lena Harder(University Children's Hospital Zurich), Martin Stanulla(Leibniz University Hannover)
Science Translational Medicine
May 18, 2016
10.1126/scitranslmed.aad2986
Cited by 119

Related Papers

Childhood Acute Lymphoblastic Leukemia: Progress Through Collaboration
|Journal of Clinical Oncology|2015|1k
Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood
|The Lancet|1998|964
Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95
|Blood|2008|607
Outcome of treatment in childhood acute lymphoblastic leukaemia with rearrangements of the 11q23 chromosomal region
|The Lancet|2002|401
Down syndrome acute lymphoblastic leukemia, a highly heterogeneous disease in which aberrant expression of CRLF2 is associated with mutated JAK2: a report from the International BFM Study Group
|Blood|2009|347